Company: HURA
Filing Date: 2025-06-06
Form Type: 8-K
Source: 0001193125-25-137135
Chunk: 2

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-06-06
Form: 8-K
Item: Item 1.01
Chunk 2
---
ants contained in such agreements may be subject to qualifications with respect to knowledge and materiality different from those applicable to security holders generally. Moreover, such representations, warranties or covenants were accurate only as of the date when made, except where expressly stated otherwise. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state of the Company’s affairs at any time.

IMPORTANT ADDITIONAL INFORMATION REGARDING PROPOSED MERGER WITH KINETA

In connection with the proposed acquisition by merger of Kineta, Inc. (“ Kineta”) by TuHURA (the “ Merger”), TuHURA filed with the U. S. Securities and Exchange Commission (the “ SEC”) a registration statement on Form S-4, dated February 7, 2025 (the “ Registration Statement”), which was declared effective on May 14, 2025, contains a joint proxy statement of Kineta and TuHURA and a prospectus of TuHURA (the “ Joint Proxy Statement/Prospectus”), and TuHURA and Kineta may file with the SEC other relevant documents regarding the Merger. Investors and securityholders of TuHURA and Kineta are urged to read the Joint Proxy Statement/Prospectus and such other materials carefully because they contain important information about TuHURA, Kineta, and the proposed Merger. This Form8-Kis not a substitute for the definitive Joint Proxy Statement/Prospectus or any other documents that TuHURA may file with the SEC or send to securityholders in connection with the proposed Merger.

A definitive copy of the definitive Joint Proxy Statement/Prospectus was mailed to Kineta and TuHURA stockholders beginning May 23, 2025. Investors and stockholders may obtain free copies of the documents filed or that will be filed with the SEC by TuHURA, through the website maintained by the SEC at www. sec. gov. The documents filed by TuHURA with the SEC may also be obtained free of charge at TuHURA’s website at www. tuhurabio. com or upon written request to: TuHURA, 10500 University Drive, Suite 110, Tampa, Florida 33612.

NO OFFER OR SOLICITATION

This Form8-Kis not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the Merger and is not intended to and does not constitute an offer to sell or the solicitation